Prosecution Insights
Prosecution Insights
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 21 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (67%) |
| Double-patenting + other | 1 (17%) |
| No statute on record | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PARKIN, JEFFREY S | 1 | 63.5% | +21.4% |
| BERTOGLIO, VALARIE E | 1 | 64.2% | +29.6% |
| RYAN, DOUGLAS CHARLES | 1 | 40.0% | +48.9% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 60.9% | +38.7% |
| SHIN, DANA H | 1 | 27.2% | +27.6% |
| WU, JULIE ZHEN QIN | 1 | 61.8% | +52.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18183082 | RNA ENCODING A TUMOR ANTIGEN | SHIN, DANA H | 58d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007468 | NUCLEIC ACID ENCODED ANTIBODY MIXTURES | WU, JULIE ZHEN QIN | 93d overdue |
| 18183082 | RNA ENCODING A TUMOR ANTIGEN | SHIN, DANA H | 58d overdue |
| 18427737 | EBOLAVIRUS AND MARBURGVIRUS VACCINES | PARKIN, JEFFREY S | 30d overdue |
| 18415477 | ARTIFICIAL NUCLEIC ACID MOLECULES | BERTOGLIO, VALARIE E | 11d overdue |
| 18553531 | SYRINGES CONTAINING PHARMACEUTICAL COMPOSITIONS COMPRISING RNA | RYAN, DOUGLAS CHARLES | 12d |
| 18320598 | RNA SEQUENCE ADAPTATION | SULLIVAN, STEPHANIE LAUREN | 62d |
| Art Unit | Apps |
|---|---|
| 1635 | 3 |
| 1671 | 1 |
| 1632 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18427737 | EBOLAVIRUS AND MARBURGVIRUS VACCINES | PARKIN, JEFFREY S | 1671 | §103 | Non-Final OA | 30d overdue | Pending | Jan 30, 2024 |
| 18415477 | ARTIFICIAL NUCLEIC ACID MOLECULES | BERTOGLIO, VALARIE E | 1632 | §103 | Final Rejection | 11d overdue | Pending | Jan 17, 2024 |
| 18553531 | SYRINGES CONTAINING PHARMACEUTICAL COMPOSITIONS COMPRISING RNA | RYAN, DOUGLAS CHARLES | 1635 | §103 | Non-Final OA | 12d | Pending | Sep 29, 2023 |
| 18320598 | RNA SEQUENCE ADAPTATION | SULLIVAN, STEPHANIE LAUREN | 1635 | DPOther | Non-Final OA | 62d | Pending | May 19, 2023 |
| 18183082 | RNA ENCODING A TUMOR ANTIGEN | SHIN, DANA H | 1635 | Other | Non-Final OA | 58d overdue | Pending | Mar 13, 2023 |
| 18007468 | NUCLEIC ACID ENCODED ANTIBODY MIXTURES | WU, JULIE ZHEN QIN | 1643 | §103 | Non-Final OA | 93d overdue | Pending | Jan 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial